Newsletters for Participants

To help participants keep in touch with Add-Aspirin news, we have set up an electronic mailing list. This means you can get your participant newsletters in email form rather than handed out in paper copy. We may also send round news about trial results via the mailing list, as well as via participants' hospitals.

Current newsletters:

Participant Newsletter Spring 2021

Participant Newsletter Spring 2020

Participant Newsletter Autumn 2019

Participant Newsletter Autumn 2018

Participant Newsletter Spring 2018

  • Signing up is entirely voluntary and you can unsubscribe whenever you like.
  • The content is mainly for participants in the Add-Aspirin trial. Other people are free to sign up (e.g. friends or relatives of participants), but they might find some content not relevant to them.
  • Add-Aspirin includes people who have had different types of cancer. We ask you to tell us which cancer you have had in case we have news to send to only some Add-Aspirin participants. However, most newsletters will be sent to all participants. We would not recommend signing up for more than one cancer type as you will often get duplicated messages.
  • We expect to send newsletters out once every 6 months.
  • The list is set up so you will only get emails from the group that are running the trial at the Medical Research Council Clinical Trials Unit at UCL; you will not receive spam or other unsolicited messages through this list.
  • You cannot respond directly to email newsletters (any replies will go to an unmonitored mailbox). If you have questions about anything in the newsletter or your participation in the study, please direct these to your study doctor or nurse.
  • Neither the study team at the Medical Research Council Clinical Trials Unit nor any staff at the hospital where you are being treated will see your name or email address in the list.
  • No one else on the mailing list will be able to see or access your name, email address, or any other information about you.
  • Your details will be used only for the purpose of sending news to this mailing list.
  • If you unsubscribe, your details will be permanently removed from the system (unless you subscribe again later).

Signing up

To sign up, please choose your cancer type from the list below, enter your email address and click ‘subscribe’.


To unsubscribe at any time, click an ‘unsubscribe’ link in any message you have received from us. As you did with subscribing, you will need to confirm via a second email. If you don’t get this confirmation email, please check your junk mail folders.


  • If you have not received a confirmation email for sign-up or unsubscribing, please check your junk mail folders, or try subscribing again.
  • If you have signed up to the wrong mailing list, please unsubscribe from the one you have joined and try again using the dropdown list above.

If you have other problems regarding the newsletters, please let your study nurse know. They can then tell us about the problems.

Contact Details

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For healthcare professionals

Please log into the members area for Add-Aspirin contact details.

Register Interest

For healthcare professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:

Register a participant

From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.

To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.

We have been experiencing intermittent issues with the trial websites. In the event of an emergency unblinding outside of office hours (including over the Easter bank holidays), if the usual unblinding links are not working, please telephone +(0)20 7670 4906 or +(0)20 7670 4892 to reach one of the Trial Managers.

Unblind a participant in the UK

Unblind a participant in the RoI

Unblind a participant in India